Alpha Teknova (NASDAQ:TKNO) Sets New 1-Year High - Should You Buy?

Key Points

• Alpha Teknova shares reached a new 52-week high of $9.41, significantly above their 50-day and 200-day moving averages of $6.71 and $4.93, respectively.
• Analyst sentiment is mixed: three analysts rate the stock Buy, one rates it Hold, and one rates it Sell. The consensus rating is Hold, with an average price target of $8.00—below the current trading price.
• The company exceeded quarterly expectations, reporting a $0.06 adjusted loss per share versus the $0.08 expected loss and revenue of $12.19 million versus the $10.95 million consensus estimate, though it remains unprofitable.

Alpha Teknova, Inc. (NASDAQ:TKNO - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Friday. The stock traded as high as $9.41 and last traded at $9.3690, with a volume of 356114 shares traded. The stock had previously closed at $9.29.

Analyst Ratings Changes

A number of research analysts recently commented on TKNO shares. BTIG Research raised Alpha Teknova from a "neutral" rating to a "buy" rating and set a $8.00 target price on the stock in a research note on Tuesday, August 11th. Wall Street Zen raised Alpha Teknova from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Weiss Ratings cut Alpha Teknova from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, August 11th. Zacks Research upgraded Alpha Teknova to a "hold" rating in a research report on Thursday, August 6th. Finally, Roth Capital started coverage on Alpha Teknova in a research report on Wednesday, August 5th. They issued a "buy" rating and a $7.00 target price for the company. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $8.00.

Alpha Teknova Stock Performance

The stock has a market cap of $506.19 million, a PE ratio of -30.28 and a beta of 0.72. The company has a fifty day moving average price of $6.71 and a 200 day moving average price of $4.93. The company has a quick ratio of 3.48, a current ratio of 4.49 and a debt-to-equity ratio of 0.21.

Alpha Teknova (NASDAQ:TKNO - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. Alpha Teknova had a negative return on equity of 24.94% and a negative net margin of 38.37%.The company had revenue of $12.19 million during the quarter, compared to analysts' expectations of $10.95 million. Analysts expect that Alpha Teknova, Inc. will post -0.28 earnings per share for the current year.

Institutional Trading of Alpha Teknova

Institutional investors have recently made changes to their positions in the stock. Roubaix Capital LLC increased its stake in shares of Alpha Teknova by 88.5% in the first quarter. Roubaix Capital LLC now owns 1,882,355 shares of the company's stock worth $5,440,000 after buying an additional 883,823 shares during the period. BlackRock Inc. bought a new stake in Alpha Teknova during the 2nd quarter valued at $4,997,000. Royce & Associates LP purchased a new stake in Alpha Teknova during the 4th quarter valued at $1,116,000. Bank of America Corp DE purchased a new stake in Alpha Teknova during the 2nd quarter valued at $1,453,000. Finally, Bank of New York Mellon Corp bought a new stake in Alpha Teknova in the 2nd quarter worth $604,000. Hedge funds and other institutional investors own 13.81% of the company's stock.

Alpha Teknova Company Profile

Alpha Teknova, Inc NASDAQ: TKNO develops and manufactures critical reagents and solutions used in life sciences research, biopharmaceutical development, and laboratory testing. The company supplies ready-to-use and custom-formulated biological buffers, media, process liquids, and other high-purity reagents designed to support research and production workflows.

Its products and services are used across applications including cell and gene therapy, molecular diagnostics, next-generation sequencing, vaccine development, and other genomics and bioprocessing activities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.